Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
H.RannevikG.KarlssonM
This is called prior authorization
doi:10.1097/ALN.0b013e318178820b
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
It should not be placed in hot or warm foods as heating food can compromise its delicate antioxidant properties
Hagman, B
US$ 25.77
US$ 22.49
US$ 29.36
